{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T04:11:42Z","timestamp":1773288702296,"version":"3.50.1"},"reference-count":65,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1097\/crd.0000000000000014","type":"journal-article","created":{"date-parts":[[2014,1,9]],"date-time":"2014-01-09T11:05:44Z","timestamp":1389265544000},"page":"140-146","source":"Crossref","is-referenced-by-count":37,"title":["Antihyperlipidemic Therapies Targeting PCSK9"],"prefix":"10.1097","volume":"22","author":[{"given":"Michael","family":"Weinreich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R3-4-20210203","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1161\/01.CIR.97.18.1837","article-title":"Prediction of coronary heart disease using risk factor categories.","volume":"97","author":"Wilson","year":"1998","journal-title":"Circulation"},{"key":"R5-4-20210203","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1001\/jama.1986.03380200061022","article-title":"Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).","volume":"256","author":"Stamler","year":"1986","journal-title":"JAMA"},{"key":"R6-4-20210203","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/0002-9149(80)90516-0","article-title":"Prevalence of coronary heart disease in the Framingham Offspring Study: role of lipoprotein cholesterols.","volume":"46","author":"Wilson","year":"1980","journal-title":"Am J Cardiol"},{"key":"R7-4-20210203","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1001\/jama.1986.03380200073024","article-title":"Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study.","volume":"256","author":"Castelli","year":"1986","journal-title":"JAMA"},{"key":"R8-4-20210203","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.clinthera.2007.05.012","article-title":"Cholesterol reduction yields clinical benefits: meta-analysis including recent trials.","volume":"29","author":"Gould","year":"2007","journal-title":"Clin Ther"},{"key":"R10-4-20210203","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1586\/14779072.1.4.495","article-title":"Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia.","volume":"1","author":"Rosenson","year":"2003","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"R11-4-20210203","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1161\/CIR.0b013e318235eb4d","article-title":"World Heart Federation and the Preventive Cardiovascular Nurses Association. AHAACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation.","volume":"124","author":"Smith","year":"2011","journal-title":"Circulation"},{"key":"R12-4-20210203","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jacl.2007.07.003","article-title":"Further reduction of low-density lipoprotein cholesterol and C-reactive protein with the addition of ezetimibe to maximum-dose rosuvastatin in patients with severe hypercholesterolemia.","volume":"1","author":"Stein","year":"2007","journal-title":"J Clin Lipidol"},{"key":"R14-4-20210203","doi-asserted-by":"crossref","first-page":"J19","DOI":"10.1016\/S1520-765X(02)90078-7","article-title":"Combination therapy: its rationale and the role of ezetimibe.","volume":"4","author":"Stone","year":"2002","journal-title":"Eur Heart J Suppl"},{"key":"R16-4-20210203","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patientsthe PRIMO study.","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"R17-4-20210203","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archinte.163.5.553","article-title":"Risk for myopathy with statin therapy in high-risk patients.","volume":"163","author":"Ballantyne","year":"2003","journal-title":"Arch Intern Med"},{"key":"R18-4-20210203","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.amjmed.2003.10.033","article-title":"Current overview of statin-induced myopathy.","volume":"116","author":"Rosenson","year":"2004","journal-title":"Am J Med"},{"key":"R19-4-20210203","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"R20-4-20210203","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"key":"R21-4-20210203","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0002-9149(03)00530-7","article-title":"STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial).","volume":"92","author":"Jones","year":"2003","journal-title":"Am J Cardiol"},{"key":"R22-4-20210203","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/qjmed\/hch035","article-title":"Severe irritability associated with statin cholesterol-lowering drugs.","volume":"97","author":"Golomb","year":"2004","journal-title":"QJM"},{"key":"R23-4-20210203","doi-asserted-by":"crossref","first-page":"c2197","DOI":"10.1136\/bmj.c2197","article-title":"Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database.","volume":"340","author":"Hippisley-Cox","year":"2010","journal-title":"BMJ"},{"key":"R24-4-20210203","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1161\/CIRCGENETICS.108.795013","article-title":"Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response.","volume":"1","author":"Voora","year":"2008","journal-title":"Circ Cardiovasc Genet"},{"key":"R25-4-20210203","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1001\/jama.291.23.2821","article-title":"Pharmacogenetic study of statin therapy and cholesterol reduction.","volume":"291","author":"Chasman","year":"2004","journal-title":"JAMA"},{"key":"R27-4-20210203","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1194\/jlr.R026658","article-title":"The PCSK9 decade.","volume":"53","author":"Lambert","year":"2012","journal-title":"J Lipid Res"},{"key":"R28-4-20210203","doi-asserted-by":"crossref","first-page":"18602","DOI":"10.1074\/jbc.M702027200","article-title":"Binding of proprotein convertase subtilisinkexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation.","volume":"282","author":"Zhang","year":"2007","journal-title":"J Biol Chem"},{"key":"R29-4-20210203","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1194\/jlr.M700071-JLR200","article-title":"Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis.","volume":"48","author":"Qian","year":"2007","journal-title":"J Lipid Res"},{"key":"R30-4-20210203","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.jacc.2013.07.056","article-title":"Targeting the proprotein convertase subtilisinkexin type 9 for the treatment of dyslipidemia and atherosclerosis.","volume":"62","author":"Urban","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R31-4-20210203","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/MOL.0b013e328361f62d","article-title":"The promises of PCSK9 inhibition.","volume":"24","author":"Petrides","year":"2013","journal-title":"Curr Opin Lipidol"},{"key":"R32-4-20210203","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1172\/JCI107332","article-title":"Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia.","volume":"52","author":"Goldstein","year":"1973","journal-title":"J Clin Invest"},{"key":"R33-4-20210203","doi-asserted-by":"crossref","first-page":"6919","DOI":"10.1073\/pnas.84.19.6919","article-title":"Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding.","volume":"84","author":"Innerarity","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R35-4-20210203","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1194\/jlr.M300203-JLR200","article-title":"Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice.","volume":"44","author":"Maxwell","year":"2003","journal-title":"J Lipid Res"},{"key":"R36-4-20210203","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1161\/01.ATV.0000134621.14315.43","article-title":"Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia.","volume":"24","author":"Dubuc","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R37-4-20210203","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1194\/jlr.M700437-JLR200","article-title":"Atorvastatin increases human serum levels of proprotein convertase subtilisinkexin type 9.","volume":"49","author":"Careskey","year":"2008","journal-title":"J Lipid Res"},{"key":"R38-4-20210203","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1073\/pnas.0409736102","article-title":"Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment.","volume":"102","author":"Maxwell","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R39-4-20210203","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"key":"R41-4-20210203","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1161\/01.ATV.0000204337.81286.1c","article-title":"Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy.","volume":"26","author":"Berge","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R42-4-20210203","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1086\/500615","article-title":"A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol.","volume":"78","author":"Kotowski","year":"2006","journal-title":"Am J Hum Genet"},{"key":"R43-4-20210203","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.0009-9163.2004.0238.x","article-title":"Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia.","volume":"65","author":"Leren","year":"2004","journal-title":"Clin Genet"},{"key":"R44-4-20210203","doi-asserted-by":"crossref","first-page":"9820","DOI":"10.1073\/pnas.0903849106","article-title":"A proprotein convertase subtilisinkexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates.","volume":"106","author":"Chan","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R45-4-20210203","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.111.057406","article-title":"Gene inactivation of proprotein convertase subtilisinkexin type 9 reduces atherosclerosis in mice.","volume":"125","author":"Denis","year":"2012","journal-title":"Circulation"},{"key":"R46-4-20210203","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa1105803","article-title":"Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.","volume":"366","author":"Stein","year":"2012","journal-title":"N Engl J Med"},{"key":"R47-4-20210203","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/j.jacc.2012.03.007","article-title":"Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisinkexin type 9 serine protease, SAR236553REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.","volume":"59","author":"McKenney","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R48-4-20210203","doi-asserted-by":"crossref","first-page":"E4E5","DOI":"10.1002\/ibd.21309","article-title":"Leukocytoclastic vasculitis: a rare adverse effect secondary to infliximab.","volume":"17","author":"Karoui","year":"2011","journal-title":"Inflamm bowel dis"},{"key":"R49-4-20210203","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1001\/archderm.142.2.246","article-title":"Rituximab-induced leukocytoclastic vasculitis: a case report.","volume":"142","author":"Kandula","year":"2006","journal-title":"Arch Dermatol"},{"key":"R50-4-20210203","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/art.1780330808","article-title":"The American College of Rheumatology 1990 criteria for the classification of hypersensitivity vasculitis.","volume":"33","author":"Calabrese","year":"1990","journal-title":"Arthritis Rheum"},{"key":"R51-4-20210203","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/art.1780370206","article-title":"Nomenclature of systemic vasculitides. Proposal of an international consensus conference.","volume":"37","author":"Jennette","year":"1994","journal-title":"Arthritis Rheum"},{"key":"R52-4-20210203","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)60771-5","article-title":"Effect of a monoclonal antibody to PCSK9, REGN727SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial.","volume":"380","author":"Stein","year":"2012","journal-title":"Lancet"},{"key":"R53-4-20210203","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1056\/NEJMoa1201832","article-title":"Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia.","volume":"367","author":"Roth","year":"2012","journal-title":"N Engl J Med"},{"key":"R54-4-20210203","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s11883-013-0310-3","article-title":"Potential of proprotein convertase subtilisinkexin type 9 based therapeutics.","volume":"15","author":"Stein","year":"2013","journal-title":"Curr Atheroscler Rep"},{"key":"R56-4-20210203","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.jacc.2012.08.986","article-title":"Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins.","volume":"60","author":"Dias","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R57-4-20210203","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2012.25790","article-title":"Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.","volume":"308","author":"Sullivan","year":"2012","journal-title":"JAMA"},{"key":"R58-4-20210203","first-page":"2782","article-title":"Goal achievement after utilizing an anti-PCSK9 antibody in statin intolerant subjects (GAUSS): interim results from a randomized, double-blind, placebo-controlled study (abstract).","volume":"126","author":"Sullivan","year":"2012","journal-title":"Circulation"},{"key":"R59-4-20210203","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/S0140-6736(12)61770-X","article-title":"LAPLACE-TIMI 57 Investigators. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisinkexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study.","volume":"380","author":"Giugliano","year":"2012","journal-title":"Lancet"},{"key":"R60-4-20210203","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/clc.22014","article-title":"Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy.","volume":"35","author":"Kohli","year":"2012","journal-title":"Clin Cardiol"},{"key":"R61-4-20210203","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1161\/CIRCULATIONAHA.113.001969","article-title":"AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.","volume":"128","author":"Desai","year":"2013","journal-title":"Circulation"},{"key":"R62-4-20210203","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jacc.2013.09.048","article-title":"AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of National Cholesterol Education Program-Adult Treatment Panel III low-density lipoprotein cholesterol goals among high-risk patients.","volume":"63","author":"Desai","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R63-4-20210203","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0140-6736(12)61771-1","article-title":"Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisinkexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study.","volume":"380","author":"Koren","year":"2012","journal-title":"Lancet"},{"key":"R64-4-20210203","first-page":"2791","article-title":"Efficacy and safety of a fully human monoclonal antibody against PCSK9 as monotherapy for hypercholesterolemia: results from the MENDEL study, a global phase 2 trial of AMG 145 (abstract).","volume":"126","author":"Koren","year":"2012","journal-title":"Circulation"},{"key":"R65-4-20210203","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","article-title":"Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisinkexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.","volume":"126","author":"Raal","year":"2012","journal-title":"Circulation"},{"key":"R66-4-20210203","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","article-title":"Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisinkexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.","volume":"126","author":"Raal","year":"2012","journal-title":"Circulation"},{"key":"R67-4-20210203","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1161\/CIRCULATIONAHA.113.007012","article-title":"Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterol-emia. 52-week results from the Open-Label Study of Long-term Evaluation Against LDL-C (OSLER) Randomized Trial.","volume":"129","author":"Koren","year":"2014","journal-title":"Circulation"},{"key":"R70-4-20210203","first-page":"2782","article-title":"Effects of 12 weeks of treatment with RN316 (PF-04950615), a humanized IgG2a monoclonal antibody binding proprotein convertase subtilisin kexin type 9, in hypercholesterolemic subjects on high and maximal dose statins (abstract).","volume":"126","author":"Gumbiner","year":"2012","journal-title":"Circulation"},{"key":"R71-4-20210203","doi-asserted-by":"crossref","first-page":"e41865","DOI":"10.1371\/journal.pone.0041865","article-title":"Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation.","volume":"7","author":"Seidah","year":"2012","journal-title":"PLoS One"},{"key":"R72-4-20210203","doi-asserted-by":"crossref","first-page":"31791","DOI":"10.1074\/jbc.M805971200","article-title":"Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels.","volume":"283","author":"Mayer","year":"2008","journal-title":"J Biol Chem"},{"key":"R73-4-20210203","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.atherosclerosis.2008.02.004","article-title":"Berberine decreases PCSK9 expression in HepG2 cells.","volume":"201","author":"Cameron","year":"2008","journal-title":"Atherosclerosis"},{"key":"R75-4-20210203","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.metabol.2008.01.037","article-title":"Combination of simvastatin with berberine improves the lipid-lowering efficacy.","volume":"57","author":"Kong","year":"2008","journal-title":"Metabolism"},{"key":"R76-4-20210203","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1038\/mtna.2012.16","article-title":"Cholesterol-lowering action of BNA based antisense oligonucleotides targeting PCSK9 in atherogenic diet-induced hypercholesterolemic mice.","volume":"1","author":"Yamamoto","year":"2012","journal-title":"Mol Ther Nucleic Acids"},{"key":"R80-4-20210203","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1194\/jlr.M033969","article-title":"PCSK9 SNP rs11591147 is associated with low cholesterol levels but not with cognitive performance or noncardiovascular clinical events in an elderly population.","volume":"54","author":"Postmus","year":"2013","journal-title":"J Lipid Res"},{"key":"R81-4-20210203","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1593\/neo.121252","article-title":"Proprotein convertase subtilisinkexin type 9 deficiency reduces melanoma metastasis in liver.","volume":"14","author":"Sun","year":"2012","journal-title":"Neoplasia"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T23:49:01Z","timestamp":1620949741000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045415-201405000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":65,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000014","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]}}}